Autism – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Autism – Pipeline Review, H1 2020’, provides an overview of the Autism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Autism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Autism and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope


– The report provides a snapshot of the global therapeutic landscape of Autism

– The report reviews pipeline therapeutics for Autism by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Autism therapeutics and enlists all their major and minor projects

– The report assesses Autism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Autism”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Autism

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4D Pharma Plc

AgeneBio Inc

AgoneX Biopharmaceuticals Inc

APeT Holding BV

AsiaBiome

Blackthorn Therapeutics Inc

BrainStorm Cell Therapeutics Inc

Cennerv Pharma (S) Pte Ltd

Cox Biosciences LLC

Curemark LLC

Cytocom Inc

Epigen Biosciences Inc

F. Hoffmann-La Roche Ltd

GW Pharmaceuticals Plc

Immuron Ltd

Insys Therapeutics Inc

Intra-Cellular Therapies Inc

Johnson & Johnson

Neurochlore

Omeros Corp

OptiNose US Inc

Ovensa Inc

Panorama Research Inc

Park Active Molecules

RespireRx Pharmaceuticals Inc

Reviva Pharmaceuticals Inc

RogCon Inc

Rugen Therapeutics R&D (Shanghai) Co Ltd

Scioto Biosciences Inc

Sengenics International Pte Ltd

Sosei Heptares

Stem Cell Medicine Ltd

Sumitomo Dainippon Pharma Co Ltd

Zelira Therapeutics Ltd

Table of Contents

Table of Contents

Introduction

Autism Overview

Autism Therapeutics Development

Autism Therapeutics Assessment

Autism Companies Involved in Therapeutics Development

Autism Drug Profiles

Autism Dormant Projects

Autism Discontinued Products

Autism Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Autism, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Autism – Pipeline by 4D Pharma Plc, H1 2020

Autism – Pipeline by AgeneBio Inc, H1 2020

Autism – Pipeline by AgoneX Biopharmaceuticals Inc, H1 2020

Autism – Pipeline by APeT Holding BV, H1 2020

Autism – Pipeline by AsiaBiome, H1 2020

Autism – Dormant Projects, H1 2020

Autism – Dormant Projects, H1 2020 (Contd..1), H1 2020

Autism – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Autism, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports